These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1086 related items for PubMed ID: 17603880

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE, Active Bacterial Core Surveillance Team.
    Clin Infect Dis; 2008 Jan 01; 46(1):1-13. PubMed ID: 18171206
    [Abstract] [Full Text] [Related]

  • 3. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A, Levi M, Boccalini S, Tiscione E, Balocchini E, Canessa C, Azzari C, Bonanni P.
    Vaccine; 2012 Oct 05; 30(45):6396-401. PubMed ID: 22921931
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team.
    Pediatrics; 2005 May 05; 115(5):1220-32. PubMed ID: 15867028
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
    Trotter CL, Gay NJ, Edmunds WJ.
    Am J Epidemiol; 2005 Jul 01; 162(1):89-100. PubMed ID: 15961591
    [Abstract] [Full Text] [Related]

  • 8. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A, Levi M, Boccalini S, Tiscione E, Ceccherini V, Taddei C, Balocchini E, Bonanni P.
    J Prev Med Hyg; 2012 Jun 01; 53(2):61-7. PubMed ID: 23240162
    [Abstract] [Full Text] [Related]

  • 9. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2013 Mar 22; 62(RR-2):1-28. PubMed ID: 23515099
    [Abstract] [Full Text] [Related]

  • 10. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG, Cavada G, Vasquez M, Shen J, Maervoet J, Klint J, Gómez JA.
    Hum Vaccin Immunother; 2021 Dec 02; 17(12):5603-5613. PubMed ID: 34890520
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
    Bröker M.
    Hum Vaccin; 2011 Aug 02; 7(8):881-2. PubMed ID: 21785283
    [Abstract] [Full Text] [Related]

  • 13. Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States.
    Mbaeyi S, Pondo T, Blain A, Yankey D, Potts C, Cohn A, Hariri S, Shang N, MacNeil JR.
    JAMA Pediatr; 2020 Sep 01; 174(9):843-851. PubMed ID: 32687590
    [Abstract] [Full Text] [Related]

  • 14. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L, Ferreira VM, Feitosa CA, Nunes AMPB, Campos LC, Sáfadi MAP.
    Hum Vaccin Immunother; 2018 May 04; 14(5):1131-1137. PubMed ID: 29236585
    [Abstract] [Full Text] [Related]

  • 15. Evolving meningococcal immunization strategies.
    Sáfadi MA, Bettinger JA, Maturana GM, Enwere G, Borrow R, Global Meningococcal Initiative.
    Expert Rev Vaccines; 2015 Apr 04; 14(4):505-17. PubMed ID: 25494168
    [Abstract] [Full Text] [Related]

  • 16. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH.
    Vaccine; 2007 Jul 20; 25(29):5433-40. PubMed ID: 17560695
    [Abstract] [Full Text] [Related]

  • 17. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.
    Vaccine; 2006 Jul 17; 24(29-30):5690-9. PubMed ID: 16735083
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT.
    Vaccine; 2015 Jan 01; 33(1):268-75. PubMed ID: 24103896
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study.
    Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME, Ladhani SN.
    Lancet Child Adolesc Health; 2022 Feb 01; 6(2):96-105. PubMed ID: 34883094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.